eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.. a little under 60% of these encounters resulted in hospitalization and of these, about 13% required intensive care.
. of migraine. more than 4 million of them have at least 15 migraine days each month. even though many drugs prevent and treat these headaches,
.
sign out
.